Skip to main content
. 2021 Mar 19;13(6):1394. doi: 10.3390/cancers13061394

Figure 4.

Figure 4

Inhibition of pancreatic adenocarcinoma formation after orthotopic implantation of Pan02 cells and consecutive injection of ADSC-shielded MYXV construct (vMyx-mLIGHT-Fluc/tdTr) or unshielded MYXV. (a) Macroscopic appearance of pancreas and spleen upon necropsy; (b) mass of pancreata and spleen (n = 6) after orthotopic injection (21 days). The data show means ± SD of two independent experiments. (* p ≤ 0.05; *** p ≤ 0.001; ns—not significant).